| TIS | Therapy-induced senescence |
| SASP | Senescence-associated secretory phenotype |
| EMT | Epithelial-to-mesenchymal transition |
| CSC | Cancer stem cell |
| MET | Mesenchymal-to-epithelial transition |
| SAS | Senescent-associated secretome |
| ECM | Extracellular matrix |
| ROS | Reactive species oxygen |
| BTZ | Bortezomib |
| TMZ | Temozolomide |
| LUAD | Lung adenocarcinoma |
| NSCLC | Non-small-cell lung cancer |
| BLCA | Bladder urothelial carcinoma |
| OXPHOS | Oxidative phosphorylation |
| AI | Artificial intelligence |
| ISRM | Immunosenescence risk model |
| ISGS | Immunosenescence gene set |
| CCS | Cellular senescence-related signature |
| CTC | Circulating tumour cell |
| EV | Extracellular vesicle |